NIHR Oncology Translational Research Collaboration (O-TRC) IO Hepatitis Survey:

The use of immunotherapy is rapidly expanding - more biologic targets, more approved treatments, more combinations in more cancer types at earlier stages. Immunotherapy induced hepatitis is a common complication typically managed with high dose corticosteroids. The management of immunotherapy hepatitis is mostly informed by expert consensus with little data to support this. This survey aims to describe the current clinical management of immunotherapy hepatitis across the UK - in particular are there areas of clinical equipoise that could be addressed by clinical trials to improve our supportive care of this common complication.